Partnership between Scitara and Veeva to bring optimised QC lab productivity to customers
Scitara and Veeva have announced a partnership to bring improved data infrastructures to the quality control process of drug and therapeutic market release.
Cloud-based laboratory software solutions provider Scitara (Marlborough, USA) have announced their partnership with life sciences cloud-computing specialists Veeva (Pleasanton, USA) to improve data integrity in the lab and maximise productivity.
Scitara will bring its scientific integration platform, SIP, and digital lab exchange DLX to complement Veeva Vault LIMS (laboratory information management system) working to streamline sample tracking, test execution, and lab processes for the optimisation of real-time batch release. The integration of Veeva Vault LIMS with Scitara’s platforms will address potential bottlenecks in the quality control of drug and therapeutic manufacturing. Customers will be provided with connected and compliant workflows, removing manual and paper-based processes and reducing the need for a second-person review. These processes will reduce the quality control timeline and accelerate the market release of a drug or therapeutic.
Scitara CEO and founder Ajit Nagral commented: “The evolution of the lab depends on a single integrated ecosystem. The same fundamental principles apply, whether handling data from the lab or manufacturing processes. Scitara’s SIP provides a core infrastructure that establishes a dialogue across all controlling systems that guide the laboratory workflow: instruments, LIMS, e-notebooks, and manufacturing execution systems as well as the way scientists and researchers exchange data too.”
Jason Boyd, Senior Director, Veeva Vault LIMS strategy, added: “Life sciences companies are striving to take control of data, gain a greater degree of accountability to regulatory health authorities, and streamline working practices. Bringing benchtop data from instruments and applications securely into Veeva Vault LIMS in real-time will eliminate the need for point-to-point integrations or manual data entry. This is critical for enabling data-driven decisions.”
Source: Scitara and Veeva partner to help companies optimize QC lab productivity - Scitara Corporation
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
News Latest updates for semaglutide: reduction of renal failure risk
Recent data presented at the 2024 European Society for Cardiology (ESC) conference analysed Novo Nordisk’s Ozempic (semaglutide) and its effectiveness in the management of chronic kidney disease (CKD). This follows previous analysis on semaglutid... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance